Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05999630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

StatusRecruiting
PhasePhase 3
Started2023-08-21
View on ClinicalTrials.gov ↗

Amendment history

2025-10-26
minor
Study Identification, Study Status, Oversight v4
Study titlerevised
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated withWith Radioactive Iodine for Thyroid Cancer
2024-10-23
minor
Study Identification, Study Status, Oversight, Contacts/Locations v3
Study sitescontacts updated at 1 of 1 site
Study titlerevised
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated Withwith Radioactive Iodine for Thyroid Cancer
2023-10-16
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-09-10→confirmed 2023-08-21
Study sites0→1
2023-08-17
minor
Study Status, Outcome Measures v1
Primary endpoints1 entry, revised
Incidence of Post-Radiotherapy Nasolacrimal Duct Obstruction (NLDO)
2023-08-13
minor
Original filing
The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
Trial Details
NCT Number NCT05999630
Lead Sponsor Vanderbilt University Medical Center
Conditions Nasolacrimal Duct Obstruction, Thyroid Cancer
Enrollment 100 participants
Start Date 2023-08-21
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-28